Ted Pellas

Ed, Head of Oncology Imaging, Oncology Clinical Development @GSK

New Providence, NJ, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Sep 2025 — Present

Ed, Head of Oncology Imaging, Oncology Clinical Development @GSK

View department →

EDUCATION

N/A

University of Pennsylvania

VMD (DVM), School of Veterinary Medicine

N/A

Penn State University

Bachelor's Degree, Animal Science

N/A

University of Pennsylvania

PhD, Experimental Pathology/Immunology

N/A

Penn State University

Master's Degree, Animal Physiology

SKILLS

InflammationCell BiologyBiotechnologyStem CellsAntibodiesClinical TrialsRegulatory AffairsLifesciencesImmunologyClinical DevelopmentRegulatory SubmissionsIn VivoMolecular BiologyClinical Study DesignTherapeutic AreasPharmacologyMedical WritingImmuno-OncologyCellLife SciencesClinical ResearchClinical PharmacologyImagingPharmaceutical IndustryDrug DiscoveryBiomarkersAutoimmune DiseasesIn VitroMedical ImagingMolecular ImagingMedicineDigital ImagingOncologyProtocolInfectious DiseasesImmunohistochemistryGlpTranslational MedicineCROCommercialization

ABOUT TED PELLAS

Exec. Dir, Imaging Lead, Oncology Clinical Development GSK R&D with extensive preclinical, translational, early, and late phase clinical imaging experience in biopharmaceutical drug development. Specialty areas include Immuno-Oncology, Oncology, Immunology, and Musculoskeletal Imaging. Proficient at leading clinical imaging strategy and execution in Oncology & IO clinical trials (immune checkpoint inhibitors/agonists, targeted therapy, cell imaging, synthetic lethality, ADCs, combination trials), with cross-portfolio standardization & harmonization (via templates, smart EDC, SDTM/CDISC output, etc.). Subject matter expert in tumor assessment criteria. Experienced in quantitative molecular PET imaging probe development using large molecule vectors (antibodies, mAb fragments, etc.) in pre-clinical development, including applications for cell imaging, T cell effector imaging, tumor imaging, etc.AREAS OF EXPERTISE & COLLABORATIONImmuno-Oncology/Oncology Clinical Research | Biologics, Antibodies, ADCs, Small Molecules | GxP, ICH; CRF, ICF | Clinical Study Protocols / Templates | Imaging CROs, Imaging Charters, DTS | CMC Biologics Manufacturing | Ad Boards, Steering Committees, Site Initiations | Budget, Portfolio & basic Project Management | Tumor Immunology, Cancer Immunotherapy: CTLA-4, PD-1, PD-L1, Nivolumab, Ipilimumab, Durvalumab, Tremelimumab, Dostarlimab; Targeted therapy: mTOR, Brivanib, IGF-1R, Jak2, CXCR4, Smoothened, Notch, Imatinib, Deferasirox | Autoimmunity (Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis): Abatacept, Clazakizumab, Canakinumab, Secukinumab | Data Visualization, Spotfire | Molecular Imaging: PET/MRI/CT/DEXA/Optical | Pharmacology; PK/PD | Mesenchymal Stem Cell tissue regeneration | Structural Biology, Molecular Pathology• Demonstrated matrix accountability and leadership skills as an Imaging SMEmisspellings Theadore Pelas Pellis Pallas

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.